Alzheimer's Disease Research Unit, Yale University School of Medicine, New Haven, CT, USA; Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA.
Department of Medicine (Geriatrics), Yale University School of Medicine, New Haven, CT, USA.
Neurobiol Aging. 2018 Oct;70:117-124. doi: 10.1016/j.neurobiolaging.2018.05.033. Epub 2018 May 31.
This study evaluated the effect of the alpha-2A-adrenoceptor agonist guanfacine on prefrontally mediated cognitive functions, as well as quality of life and global function in healthy older participants. One hundred twenty-three participants aged 75 years and older were randomly assigned to guanfacine 0.5 mg, 0.1 mg, or placebo daily for 12 weeks. The primary outcome measure was the change in z-score for 6 prefrontal executive function tasks over 12 weeks (PEF6). Neither dose of guanfacine improved PEF6 z-score relative to placebo. The rate of mean change (95% confidence interval) in PEF6 z-score over 12 weeks was 0.270 (0.159, 0.380) for placebo, compared with 0.121 (0.011, 0.232) for guanfacine 0.1 mg (p = 0.06, compared to placebo) and 0.213 (0.101, 0.324) for 0.5 mg (p = 0.47). Neither dose of guanfacine improved the quality of life or global function relative to placebo. Among common adverse events, only dry mouth was significantly more frequent on guanfacine compared to placebo. Guanfacine failed to ameliorate prefrontal cognitive function in older individuals, who were cognitively normal for age.
这项研究评估了α-2A-肾上腺素受体激动剂胍法辛对前额叶介导的认知功能、生活质量和健康老年人整体功能的影响。123 名年龄在 75 岁及以上的参与者被随机分配每天服用胍法辛 0.5mg、0.1mg 或安慰剂，持续 12 周。主要观察指标为 12 周内 6 项前额叶执行功能任务 z 分数的变化（PEF6）。与安慰剂相比，两种剂量的胍法辛均未改善 PEF6 z 分数。PEF6 z 分数在 12 周内的平均变化率（95%置信区间）为安慰剂组 0.270（0.159，0.380），而胍法辛 0.1mg 组为 0.121（0.011，0.232）（p=0.06，与安慰剂相比），0.5mg 组为 0.213（0.101，0.324）（p=0.47）。与安慰剂相比，两种剂量的胍法辛均未改善生活质量或整体功能。在常见的不良反应中，只有口干在胍法辛组比安慰剂组更常见，且具有统计学意义。胍法辛未能改善认知正常的老年人的前额叶认知功能。
